HCV: Continuing Advances From Individual Cure to Disease Elimination
Source: HCV: Continuing Advances From Individual Cure to Disease Elimination

Table of Contents

 

Slideset

HCV: Continuing Advances From Individual Cure to Disease Elimination

In this downloadable slideset, Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; Ira M. Jacobson, MD; and Norah Terrault, MD, MPH, review strategies for eliminating HCV infection, both at the individual level and at the population level. The slideset includes a review of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients, through to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
Format: Microsoft PowerPoint (.ppt)
File size: 3.07 MB
Date posted: 12/7/2016
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015    2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C

    Mark S. Sulkowski MD - 9/15/2015    14 comments / Last Comment: 6/25/2016
    Using a recent case patient, I outline my current approach to using HCV resistance testing to select therapy in patients who have previously received an HCV NS5A inhibitor.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016    6 comments / Last Comment: 6/25/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.